123I is a kind of radionuclide produced by an accelerator with the half-life of 13.2 hours and emit the fay of which the main photon is 159keV; when it is used for the imaging, it has small radiation dose and good imaging effect, and allow for multiple repeated imaging, so it is considered to be the Single-Photon Emission Computed Tomography (SPECT) nuclide with the ideal nuclide properties. 123I and its labeled compound have been widely used for the research and clinical diagnosis of cardiology, neurology and oncology in developed countries. In particular, 123I-labeled monoclonal antibodies and receptor ligand biomolecular analogues have been widely used in the clinical research of nuclear medicine.
Through nearly a decade of research, HTA Co., Ltd. has successfully established the cyclotron gas target system, nuclide separatino and purification system for the production of 123I nuclide, which completes the research of separation and purification process. If there is enough demand, one batch can be supplied every day with the batch production greater than 3Ci (up to 4Ci) and the output reached the international level of 8mCi/μA·h. The product technical specifications are as follows: NaOH solution for which nuclear-purity is greater than 99.8%, radiochemical purity is greater than 95%, concentration is greater than 500mCi/mL, and solvent is 0.1mol/L.
Drugs which are related to 123I nuclide and internationally approved currently include 123I capsule, 123I oral solution, 123I-MIBG and 123I-ioflupane. 123I capsule and 123I oral solution are mainly used for the diagnosis of thyroid disease. 123I-MIBG is used for the diagnosis of pheochromocytoma and neuroblastoma, and also as a sympathetic contrast agent for the diagnosis of heart failure. 123I-ioflupane is mainly used for the early diagnosis of Parkinson. In addition, iodine-123-ADAM, a serotonin transporter contrast agent has also entered into phase II clinical trial.
